Interface strains and lattice distortion are inevitable issues during perovskite crystallization. Silane as a coupling agent is a popular connector to enhance the compatibility between inorganic and organic materials in semiconductor devices. Herein, a protonated amine silane coupling agent (PASCA‐Br) interlayer between TiO2 and perovskite layers is adopted to directionally grasp both of them by forming the structural component of a lattice unit. The pillowy alkyl ammonium bromide terminals at the upper side of the interlayer provide well‐matched growth sites for the perovskite, leading to mitigated interface strain and ensuing lattice distortion; meanwhile, its superior chemical compatibility presents an ideal effect on healing the under‐coordinated Pb atoms and halogen vacancies of bare perovskite crystals. The PASCA‐Br interlayer also serves as a mechanical buffer layer, inducing less cracked perovskite film when bending. The developed molecular‐level flexible interlayer provides a promising interfacial engineering for perovskite solar cells and their flexible application.
Metal halide perovskite semiconductors have demonstrated remarkable potentials in solution‐processed blue light‐emitting diodes (LEDs). However, the unsatisfied efficiency and spectral stability responsible for trap‐mediated non‐radiative losses and halide phase segregation remain the primary unsolved challenges for blue perovskite LEDs. In this study, it is reported that a fluorene‐based π‐conjugated cationic polymer can be blended with the perovskite semiconductor to control film formation and optoelectronic properties. As a result, sky‐blue and true‐blue perovskite LEDs with Commission Internationale de l'Eclairage coordinates of (0.08, 0.22) and (0.12, 0.13) at the record external quantum efficiencies of 11.2% and 8.0% were achieved. In addition, the mixed halide perovskites with the conjugated cationic polymer exhibit excellent spectral stability under external bias. This result illustrates that π‐conjugated cationic polymers have a great potential to realize efficient blue mixed‐halide perovskite LEDs with stable electroluminescence.
Metal halide-based perovskites are regarded as promising candidates for light-emitting diodes (LEDs) owing to their high color purity, tunable bandgap and solution processability.
In prostate cancer cell line, LNCaP, emodin inhibites the proliferation by AR and p53-p21 pathways, and induces apoptosis via the mitochondrial pathway.
Perovskite‐based light‐emitting diodes (PeLEDs) have exhibited promising potential; however, their operational lifetimes are far from expectation. The large bias of the device during operation has been demonstrated as one of main reasons for accelerated device failure. To mitigate such a predicament, interfacial Auger effect (IAE) assisted sub‐bandgap voltage electroluminescence (EL) is a potential pathway to decrease the electric field intensity in each functional layer. However, the properties of a desirable IAE are still poorly understood. Herein, the underlying mechanism of IAE based on the injection characteristics of interfacial minority carriers at the Auger effect interface is investigated. Consequently, the prerequisites and the secondary conditions for the realization of IAE are proposed. Taking advantage of IAE assisted EL, the fabricated PeLEDs exhibit ultralow operational voltage, ignorable roll‐off, and improved operational stability. The findings in this work not only pave the way toward a feasible approach to enhance the stability of PeLEDs, but also highlight the potential of sub‐bandgap voltage EL in future display and lighting applications, especially in series circuits and tandem structures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.